- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05695963
Ecological Momentary Assessment in Patients With Restless Legs Syndrome (DAILY-REST)
January 18, 2024 updated by: University Hospital, Bordeaux
Feasibility, Validity and Clinical Utility of Ecological Momentary Assessment in Patients With Restless Legs Syndrome: a Prospective Study. DAILY-REST
The Restless Legs Syndrome (RLS) is a sensorimotor disorder better characterized by an urge to move the legs at rest.
Although treatments are available, many patients experience periods of symptoms relief and exacerbation.
Whether this is due to the natural history of the disease or to health-related behaviors of daily life is presently unknown.
The primary objective is to examine the feasibility of mobile technology to assess RLS symptoms severity fluctuations in daily life by collecting real-time data.
The secondary objectives will be to examine the validity of this technic in the context of RLS and to use these real-time data to identify daily life risk factors for symptom onset or aggravation.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The Restless Legs Syndrome is a common sensorimotor disorder that disturbs sleep and quality of life.
One of the key diagnostic criteria of RLS is the complaint of an irresistible urge to move the legs.
This urge to move is often triggered by unpleasant sensations; it occurs at rest, particularly late in the day or at sleep time, and is temporarily relieved with movement.
The negative impact on quality of life is profound and the disease is associated with a substantial economic burden.
Dopamine agonists show efficacy which is, however, moderate, and many patients do not experience full remission.
Tolerance, paradoxical aggravation of RLS symptoms (dopamine-induced augmentation) and impulse control disorders are frequently seen in patients with RLS on dopamine agonists.
Therefore, although medications are available, many patients either experience side effects or show treatment response fluctuations with periods of symptoms' remission/alleviation or exacerbation.
Whether RLS symptom fluctuation is related to the natural history of the disease (independent of appropriate medical treatment) is presently unknown.
Furthermore, it is unknown if such fluctuation may be due to the impact of health-related behaviors in the context of daily life (e.g.
physical activity, sleep quality, mood, alcohol consumption, smoking, or specific food intake), although this question warrants further research as any potential association would provide important opportunities for prevention and intervention strategies.
For these reasons, the investigators aim to test the feasibility, validity and clinical utility of ambulatory monitoring techniques such as Ecological Momentary Assessment (EMA) to document RLS symptoms severity and risk factors in daily life by collecting real-time data, and by using such information to reduce risk factor exposure and thus improve symptoms.
Eligible participants will be given a study-dedicated smartphone to carry with them for a two-week period and will be equipped with wearable actigraph for the same period to monitor activity-rest cycle.
Study Type
Interventional
Enrollment (Estimated)
62
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Imad Marc Antoine GHORAYEB, MD, PhD
- Phone Number: +33 (0)5.56.79.55.13
- Email: marc-antoine.ghorayeb@chu-bordeaux.fr
Study Contact Backup
- Name: Olivier BRANCHARD
- Phone Number: +33 (0)5.57.82.06.97
- Email: olivier.branchard@chu-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France
- Recruiting
- CHU de Bordeaux - Neurophysiologie Clinique de l'Enfant et de l'Adulte
-
Contact:
- Olivier BRANCHARD
- Phone Number: +33 (0)5.57.82.06.97
- Email: olivier.branchard@chu-bordeaux.fr
-
Contact:
- Imad Marc-Antoine GHORAYEB, MD, PhD
- Phone Number: +33 (0)5.56.79.55.13
- Email: marc-antoine.ghorayeb@chu-bordeaux.fr
-
Principal Investigator:
- Imad Marc-Antoine GHORAYEB, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient over 18 years old and less than 65
- Any patient with a diagnosis of idiopathic RLS based on medical history and the presence of the 5 RLS diagnostic criteria
- Normal clinical examination
- Person affiliated or benefiting from a social security scheme
- Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research).
Exclusion Criteria:
- Any significant psychiatric illness (schizophrenia, bipolar disorder, severe depression, dementia, obsessive compulsive disorder, attention-deficit/hyperactivity disorder ...) or mood disorder
- History or presence of chronic pain other than that associated with RLS, history of epilepsy or serious head injury, history of peripheral neuropathy, diabetes
- Clinically significant sleep apnea, narcolepsy, or any secondary causes of RLS (e.g. chronic renal failure/hemodialysis, pregnancy)
- Other active clinically significant illness, including unstable cardiovascular, or neoplasic pathology which could interfere with the study conduct or interfere with study assessments or compromise the study participation
- Pregnant or breastfeeding woman
- Persons referred to in articles L.1121-5 to L.1121-8 (persons deprived of liberty by judicial or administrative decision, minors, adults subject to a legal protection measure or unable to express their consent).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Restless Legs Syndrome
|
RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of Ecological Momentary Assessment (EMA)
Time Frame: 14 days after baseline (Day 0)
|
This outcome measure is composite and will be established by:
|
14 days after baseline (Day 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validity of Ecological Momentary Assessment (EMA)
Time Frame: 14 days after baseline (Day 0)
|
This outcome measure is composite and will be established by:
|
14 days after baseline (Day 0)
|
Risk factors for RLS
Time Frame: Between baseline (day 0) and 14 days after baseline
|
To examine if specific daily-life behaviors or experiences on any given day as assessed by EMA (activities, environments, psychological states and mood, substance use, food, sleep habits and quality) are prospectively associated with the frequency or severity of RLS symptoms later that evening/night.
|
Between baseline (day 0) and 14 days after baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Imad Marc Antoine GHORAYEB, MD, PhD, CHU Bordeaux
- Study Chair: Gwénaëlle CATHELINE, PhD, Université de Bordeaux - INCIA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2024
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
January 13, 2023
First Submitted That Met QC Criteria
January 13, 2023
First Posted (Actual)
January 25, 2023
Study Record Updates
Last Update Posted (Estimated)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 18, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2022/30
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedIdiopathic Restless Legs SyndromeGermany
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedIdiopathic Restless Legs SyndromeUnited States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
Clinical Trials on Clinical assessment
-
Thomas Jefferson UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Florida International UniversityNational Institute of Mental Health (NIMH); University of MiamiCompletedDisruptive BehaviorUnited States
-
Fondazione Don Carlo Gnocchi OnlusCompletedChronic Low-back PainItaly
-
Czech Technical University in PragueMayo Clinic; University Hospital, Montpellier; McGill University Health Centre... and other collaboratorsUnknownParkinson Disease | REM Sleep Behavior DisorderUnited States, Canada, Austria, Czechia, France, Germany, Italy
-
Halic UniversityCompletedTemporomandibular Joint Dysfunction SyndromeTurkey
-
Assiut UniversityNot yet recruitingFeeding; Difficult, Newborn | Pre-Term
-
NHS Greater Glasgow and ClydeBiogenEnrolling by invitationRelapsing Remitting Multiple SclerosisUnited Kingdom
-
University Hospital, MontpellierUnknown
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenRecruiting